268 related articles for article (PubMed ID: 35700381)
1. Cost-effectiveness of polatuzumab vedotin combined with chemoimmunotherapy in untreated diffuse large B-cell lymphoma.
Kambhampati S; Saumoy M; Schneider Y; Pak S; Budde LE; Mei MG; Siddiqi T; Popplewell LL; Wen YP; Zain J; Forman SJ; Kwak LW; Rosen ST; Danilov AV; Herrera AF; Thiruvengadam NR
Blood; 2022 Dec; 140(25):2697-2708. PubMed ID: 35700381
[TBL] [Abstract][Full Text] [Related]
2. US cost-effectiveness analysis of polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma.
Matasar M; Masaquel A; S Ho R; Launonen A; Ng CD; Wang R; Fox D; Hossain F; Li J; Burke JM
J Med Econ; 2023; 26(1):1134-1144. PubMed ID: 37674384
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of combination therapy of polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisolone for previously untreated diffuse large B-cell lymphoma in Japan.
Mizuoka T; Sakamaki H; Fuji S; Saito S; Murata T; Ohno S; Inubashiri N; Oshima T; Yamamoto K
J Med Econ; 2023; 26(1):1122-1133. PubMed ID: 37656225
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of polatuzumab vedotin in combination with chemoimmunotherapy (pola-R-CHP) in previously untreated diffuse large B-cell lymphoma in Germany.
Kambhampati S; Shumilov E; Saumoy M; Herrera AF; Tilly H; Lenz G; Thiruvengadam NR
Br J Haematol; 2023 Aug; 202(4):771-775. PubMed ID: 37188351
[TBL] [Abstract][Full Text] [Related]
5. Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma.
Tilly H; Morschhauser F; Sehn LH; Friedberg JW; Trněný M; Sharman JP; Herbaux C; Burke JM; Matasar M; Rai S; Izutsu K; Mehta-Shah N; Oberic L; Chauchet A; Jurczak W; Song Y; Greil R; Mykhalska L; Bergua-Burgués JM; Cheung MC; Pinto A; Shin HJ; Hapgood G; Munhoz E; Abrisqueta P; Gau JP; Hirata J; Jiang Y; Yan M; Lee C; Flowers CR; Salles G
N Engl J Med; 2022 Jan; 386(4):351-363. PubMed ID: 34904799
[TBL] [Abstract][Full Text] [Related]
6. Polatuzumab vedotin in previously untreated DLBCL: an Asia subpopulation analysis from the phase 3 POLARIX trial.
Song Y; Tilly H; Rai S; Zhang H; Jin J; Goto H; Terui Y; Shin HJ; Kim WS; Cao J; Feng J; Eom HS; Kim TM; Tsai XC; Gau JP; Koh H; Zhang L; Song Y; Yang Y; Li W; Huang H; Ando K; Sharman JP; Sehn LH; Bu L; Wang X; Jiang Y; Hirata J; Lee C; Zhu J; Izutsu K
Blood; 2023 Apr; 141(16):1971-1981. PubMed ID: 36626583
[TBL] [Abstract][Full Text] [Related]
7. Cost-Effectiveness Analysis of Frontline Polatuzumab-Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone and/or Second-Line Chimeric Antigen Receptor T-Cell Therapy Versus Standard of Care for Treatment of Patients With Intermediate- to High-Risk Diffuse Large B-Cell Lymphoma.
Vijenthira A; Kuruvilla J; Crump M; Jain M; Prica A
J Clin Oncol; 2023 Mar; 41(8):1577-1589. PubMed ID: 36315922
[TBL] [Abstract][Full Text] [Related]
8. Superiority of polatuzumab vedotin over other novel agents in previously untreated ABC-type diffuse large B-cell lymphoma: a network meta-analysis of 20 RCTs.
Sheng Z; Li D; Chen B; Zhao C; Zhang W; Ding B; Wang L
Ann Hematol; 2023 May; 102(5):1011-1017. PubMed ID: 36947214
[TBL] [Abstract][Full Text] [Related]
9. Comparison of statistical methods for extrapolating survival in previously untreated diffuse large B-cell lymphoma: results based on the POLARIX study.
Ho RS; Launonen A
J Med Econ; 2023; 26(1):1178-1189. PubMed ID: 37702406
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of polatuzumab vedotin in combination with R/G-CHP in patients with B-cell non-Hodgkin lymphoma.
Shemesh CS; Agarwal P; Lu T; Lee C; Dere RC; Li X; Li C; Jin JY; Girish S; Miles D; Lu D
Cancer Chemother Pharmacol; 2020 May; 85(5):831-842. PubMed ID: 32222808
[TBL] [Abstract][Full Text] [Related]
11. Comparison of best supportive care, CHOP, or R-CHOP for treatment of diffuse large B-cell lymphoma in Malawi: a cost-effectiveness analysis.
Painschab MS; Kohler R; Kimani S; Mhango W; Kaimila B; Zuze T; Mithi V; Kasonkanji E; Mumba N; Nyasosela R; Wheeler S; Gopal S
Lancet Glob Health; 2021 Sep; 9(9):e1305-e1313. PubMed ID: 34303416
[TBL] [Abstract][Full Text] [Related]
12. Polatuzumab Vedotin for the Front-Line Treatment of Diffuse Large B-Cell Lymphoma: A New Standard of Care?
Davis JA; Shockley A; Herbst A; Hendrickson L
J Adv Pract Oncol; 2023 Jan; 14(1):67-72. PubMed ID: 36741209
[TBL] [Abstract][Full Text] [Related]
13. Polatuzumab vedotin with infusional chemotherapy for untreated aggressive B-cell non-Hodgkin lymphomas.
Lynch RC; Poh C; Ujjani CS; Warren EH; Smith SD; Shadman M; Morris K; Lee S; Rasmussen H; Ottemiller S; Shelby M; Keo S; Verni K; Kurtz DM; Alizadeh AA; Chabon JJ; Hogan GJ; Schulz A; Gooley T; Voutsinas JM; Gopal AK
Blood Adv; 2023 Jun; 7(11):2449-2458. PubMed ID: 36521030
[TBL] [Abstract][Full Text] [Related]
14. Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b-2 study.
Tilly H; Morschhauser F; Bartlett NL; Mehta A; Salles G; Haioun C; Munoz J; Chen AI; Kolibaba K; Lu D; Yan M; Penuel E; Hirata J; Lee C; Sharman JP
Lancet Oncol; 2019 Jul; 20(7):998-1010. PubMed ID: 31101489
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma.
Patel KK; Isufi I; Kothari S; Foss F; Huntington S
Leuk Lymphoma; 2020 Dec; 61(14):3387-3394. PubMed ID: 32835553
[TBL] [Abstract][Full Text] [Related]
16. Current Frontline Treatment of Diffuse Large B-Cell Lymphoma.
Spinner MA; Advani RH
Oncology (Williston Park); 2022 Jan; 36(1):51-58. PubMed ID: 35089671
[TBL] [Abstract][Full Text] [Related]
17. Pola-R-CHP for frontline therapy in DLBCL: Are we saving money by spending more?
Vitolo U; Frascione PMM; Bonello F
Br J Haematol; 2023 Aug; 202(4):731-733. PubMed ID: 37313856
[TBL] [Abstract][Full Text] [Related]
18. Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma.
Younes A; Sehn LH; Johnson P; Zinzani PL; Hong X; Zhu J; Patti C; Belada D; Samoilova O; Suh C; Leppä S; Rai S; Turgut M; Jurczak W; Cheung MC; Gurion R; Yeh SP; Lopez-Hernandez A; Dührsen U; Thieblemont C; Chiattone CS; Balasubramanian S; Carey J; Liu G; Shreeve SM; Sun S; Zhuang SH; Vermeulen J; Staudt LM; Wilson W;
J Clin Oncol; 2019 May; 37(15):1285-1295. PubMed ID: 30901302
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of brentuximab vedotin with chemotherapy in treatment of CD30-expressing PTCL.
Feldman T; Zou D; Rebeira M; Lee J; Fanale M; Manley T; Rao S; Feliciano J; Harris M; Kansal A
Am J Manag Care; 2020 Feb; 26(2):e41-e49. PubMed ID: 32059099
[TBL] [Abstract][Full Text] [Related]
20. Rituximab (MabThera) for aggressive non-Hodgkin's lymphoma: systematic review and economic evaluation.
Knight C; Hind D; Brewer N; Abbott V
Health Technol Assess; 2004 Sep; 8(37):iii, ix-xi, 1-82. PubMed ID: 15361313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
